“`html
Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has announced a non-brokered private placement of debenture units. The company aims to raise up to $1.2 million through the offering of units priced at $1,000 each.
Each unit comprises an 8.0% convertible debenture with a two-year maturity and 1,666 common share purchase warrants. The debentures are convertible into common shares at $0.60 per share, while warrants are exercisable at $0.75 per share for two years. Interest payments will be made annually either in shares at the conversion price or in cash at the company’s discretion.
Defence Therapeutics (OTCQB: DTCFF), azienda biotecnologica specializzata in tecnologie di somministrazione dei farmaci, ha annunciato un collocamento privato non assistito da intermediari di unità obbligazionarie. L’obiettivo è raccogliere fino a $1,2 milioni mediante l’offerta di unità al prezzo di $1.000 ciascuna.
Ciascuna unità include un debito convertibile all’8,0% con scadenza a due anni e 1.666 warrant per l’acquisto di azioni ordinarie. I debentures sono convertibili in azioni ordinarie al prezzo di $0,60 per azione, mentre i warrant possono essere esercitati a $0,75 per azione per un periodo di due anni. I pagamenti degli interessi saranno effettuati annualmente, a discrezione della società, in azioni al prezzo di conversione o in contanti.
Defence Therapeutics (OTCQB: DTCFF), una empresa biotecnológica centrada en tecnologías de administración de fármacos, ha anunciado una colocación privada no intermediada de unidades de obligaciones. La compañía pretende recaudar hasta $1,2 millones mediante la oferta de unidades a $1.000 cada una.
Cada unidad consta de un debenture convertible al 8,0% con vencimiento a dos años y 1.666 warrants para comprar acciones ordinarias. Los debentures son convertibles en acciones ordinarias a $0,60 por acción, y los warrants pueden ejercerse a $0,75 por acción durante dos años. Los pagos de intereses se efectuarán anualmente, a elección de la compañía, en acciones al precio de conversión o en efectivo.
Defence Therapeutics (OTCQB: DTCFF)는 약물 전달 기술에 주력하는 생명공학 기업으로, 중개인 없이 진행되는 사모 전환사채(Unit) 발행을 발표했습니다. 회사는 단위당 $1,000에 최대 $120만을 조달하는 것을 목표로 하고 있습니다.
각 유닛은 만기 2년의 연 8.0% 전환사채와 1,666주의 보통주 매수 워런트로 구성됩니다. 전환사채는 주당 $0.60에 보통주로 전환 가능하며, 워런트는 2년 동안 주당 $0.75에 행사할 수 있습니다. 이자 지급은 매년 회사 재량에 따라 전환가격으로 산정한 주식으로 하거나 현금으로 지급됩니다.
Defence Therapeutics (OTCQB: DTCFF), une société de biotechnologie spécialisée dans les technologies d’administration de médicaments, a annoncé un placement privé sans courtier d’unités de débentures. La société vise à lever jusqu’à 1,2 M$ par l’offre d’unités au prix de 1 000 $ chacune.
Chaque unité comprend une débenture convertible à 8,0% échéant dans deux ans et 1 666 bons de souscription d’actions ordinaires. Les débentures sont convertibles en actions ordinaires au prix de 0,60 $ par action, tandis que les bons sont exerçables à 0,75 $ par action pendant deux ans. Les intérêts seront payés annuellement, au choix de la société, soit en actions au prix de conversion, soit en espèces.
Defence Therapeutics (OTCQB: DTCFF), ein Biotechnologieunternehmen mit Schwerpunkt auf Wirkstoff-Delivery-Technologien, hat eine nicht über einen Broker vermittelte Privatplatzierung von Debenture-Einheiten angekündigt. Ziel ist es, bis zu $1,2 Millionen durch das Angebot von Einheiten zum Preis von $1.000 pro Einheit zu beschaffen.
Jede Einheit besteht aus einem 8,0%igen wandelbaren Debenture mit einer Laufzeit von zwei Jahren und 1.666 Bezugsrechten auf Stammaktien (Warrants). Die Debentures sind zu $0,60 je Aktie wandelbar, während die Warrants für zwei Jahre zu $0,75 je Aktie ausübbar sind. Zinszahlungen erfolgen jährlich und werden nach Wahl des Unternehmens entweder in Aktien zum Wandlungspreis oder in bar geleistet.
Negative
- Dilutive impact on existing shareholders upon conversion or warrant exercise
- 8.0% interest rate represents significant cost of capital
- Unsecured nature of debentures increases risk for investors
08/22/2025 – 08:30 PM
Montreal, Quebec – Defence Therapeutics Inc. (DTCFF), a biotechnology firm making waves in the drug delivery space, is tapping the private markets for a fresh injection of capital. The company announced plans late Friday to raise up to $1.2 million through a non-brokered private placement of debenture units.
The offering, structured to entice investors, prices each unit at $1,000. Inside each unit, investors will find an 8.0% convertible debenture, maturing in two years, alongside 1,666 warrants exercisable for common shares.
Here’s the breakdown: The debentures offer an opportunity to convert into common shares at a rate of $0.60 per share. Meanwhile, the warrants, representing a leveraged bet on Defence Therapeutics’ future, are exercisable at $0.75 per share within a two-year window.
Insiders are watching closely to see how the company manages the interest payments. Defence Therapeutics retains the flexibility to settle these obligations annually, either through a share issuance at the conversion price or by disbursing cash, depending on the company’s financial position and strategic priorities.
The company emphasized that all securities issued under this placement will be subject to a standard four-month and one-day hold period, aligning with securities regulations. The closing of the offering hinges on securing the necessary regulatory approvals. Defence Therapeutics also reserved the option to compensate finders involved in the offering, adhering to Canadian Securities Exchange guidelines.
Defence Therapeutics, in its corporate profile, positions itself as a clinical-stage innovator focused on next-generation antibody-drug conjugates (ADCs). Its ACCUM platform aims to deliver ADCs intact to target cells, theoretically boosting efficacy against cancer.
The Bottom Line: While the non-brokered private placement provides Defence Therapeutics with needed capital, investors should be aware of potential dilution and the implications of the 8.0% interest rate on unsecured debentures. Keep an eye on how the company will manage the interest payments, whether with shares or cash, and on the future development of their exciting ADC programs.
FAQ
What are the key terms of Defence Therapeutics (DTCFF) debenture offering in August 2025?
The offering consists of $1,000 units including an 8.0% convertible debenture and 1,666 warrants. Debentures are convertible at $0.60 per share with warrants exercisable at $0.75 for two years.
How much is Defence Therapeutics (DTCFF) planning to raise through this debenture offering?
Defence Therapeutics aims to raise up to $1.2 million through this non-brokered private placement of debenture units.
What is the interest rate and maturity period for Defence Therapeutics’ August 2025 convertible debentures?
The convertible debentures carry an 8.0% annual interest rate and will mature two years following the issue date.
How will Defence Therapeutics (DTCFF) pay interest on these convertible debentures?
Interest will be paid annually either in shares at the $0.60 conversion price or in cash, at the company’s discretion.
What is the holding period for securities issued in Defence Therapeutics’ August 2025 offering?
All securities issued will be subject to a statutory hold period of four months and one day following the closing date.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/7904.html
